Hofling M, Ma L, Sahlin L, Haglund C, Nordling S, von Schoultz B, Cline J M
Department of Woman and Child Health, Karolinska Institute and Hospital, Stockholm, Sweden.
Climacteric. 2009 Feb;12(1):72-9. doi: 10.1080/13697130802448387.
To analyze the expression of the androgen receptor(AR) and syndecan-1 in breast tissue during long-term hormonal treatment in cynomolgus monkeys.
Sixty oophorectomized macaques were randomized to receive either tibolone, conjugated equine estrogens (CEE), CEE + medroxyprogesterone acetate (MPA) or no hormonal treatment. Breast tissue was collected at necropsy after 2 years and stained for AR and syndecan-1.
Apparent differences were seen between treatment groups as compared to untreated animals. AR expression was markedly increased by tibolone and suppressed by combined CEE/MPA. Both treatments increased syndecan-1 in stromal tissue, whereas CEE alone had no significant effect.
We found alternative regimens for hormonal therapy to differ in their influence on two markers of importance for the development of breast cancer. The results may be relevant for the ongoing clinical discussion on the long-term safety of different hormonal treatments.
分析食蟹猴长期激素治疗期间乳腺组织中雄激素受体（AR）和syndecan-1的表达情况。
将60只去卵巢的猕猴随机分为四组，分别接受替勃龙、结合马雌激素（CEE）、CEE + 醋酸甲羟孕酮（MPA）治疗或不接受激素治疗。2年后尸检时收集乳腺组织，并进行AR和syndecan-1染色。
与未治疗的动物相比，各治疗组之间存在明显差异。替勃龙显著增加AR表达，而CEE/MPA联合治疗则抑制AR表达。两种治疗均增加了基质组织中的syndecan-1，而单独使用CEE则无显著影响。
我们发现不同的激素治疗方案对乳腺癌发生发展的两个重要标志物的影响不同。这些结果可能与当前关于不同激素治疗长期安全性的临床讨论相关。
